Skip to main content
. 2013 Feb 22;2(1):e000067. doi: 10.1161/JAHA.112.000067

Table 2.

Mean i‐TTR by Baseline Characteristics: Medication Use

Baseline Variable N i‐TTR Mean % Univariable P Value
Prior VKA experience <0.0001
VKA naïve 2596 (37) 47.4±22.1
VKA experienced but warfarin naïve 1334 (19) 56.9±19.0
Warfarin experienced 3053 (44) 61.1±19.3
Aspirin <0.0001
Absence 4949 (71) 56.4±20.8
Presence 2034 52.2±22.1
ACE inhibitor 0.070
Absence 3223 55.7±21.3
Presence 3760 (54) 54.8±21.2
ACE inhibitor or ARB 0.86
Absence 1808 55.3±21.4
Presence 5175 (74) 55.2±21.2
Amiodarone <0.0001
Absence 6444 55.7±21.2
Presence 539 (8) 49.3±20.6
Digitalis 0.0037
Absence 4278 55.8±21.3
Presence 2705 (39) 54.3±21.2
β‐Blocker 0.0003
Absence 2411 53.9±21.8
Presence 4572 (65) 55.8±21.0
Loop diuretic 0.75
Absence 4577 55.1±21.3
Presence 2406 (34) 55.3±21.3
Statin <0.0001
Absence 3968 52.7±21.6
Presence 3015 (43) 58.4±20.3

There were no missing data for this Table. i‐TTR indicates individual patient‐level time in therapeutic range; VKA, vitamin K antagonist; ACE, angiotensin‐converting enzyme; ARB, angiotensin receptor blocker.